Dr. Antoine Yver serves as Chairman of Development at Centessa Pharmaceuticals. Antoine brings more than 30 years of global experience in the pharmaceutical industry to Centessa and has led the approvals of 11 drugs, including TAGRISSO®, LYNPARZA®, and ENHERTU®. He led the development of TAGRISSO® in 2 years and 7 months from first human dose to US approval and its rapid deployment to all other major regions, which was the fastest ever for an anti-cancer drug. Antoine joined Centessa from Daiichi Sankyo Company, Ltd., where he served as executive vice president and global head, R&D oncology, and chair of the cancer enterprise. Antoine currently serves as an independent director on the board of Sanofi (NASDAQ: SNY) and as an independent board member on the board of Spotlight Therapeutics.
Previously, Antoine was with AstraZeneca, PLC, most recently serving as senior vice president, global medicine head, oncology, and global medicines development China lead.
Earlier, Antoine held various clinical development roles at Schering-Plough/Merck, Johnson & Johnson, Aventis Pharmaceuticals, Inc., Rhône-Poulenc Rorer, Inc., Applied Immune Sciences, Inc., and Chugai-RP.
Antoine is a pediatric oncologist and holds an MD degree from Université Paris-Saclay.
